Vascular targeting therapy: Potential benefit depends on tumor and host related effects

Experimental Oncology

Volumn 32, Issue 3, 2010, Pages 143-148

  Horsman, M R ^a   Bohn, A B ^a   Busk, M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiogenesis; Vascular disrupting agents; Vascular targeting agents

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULAR TARGETING AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGY; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; APNEA; ARTHRALGIA; ATAXIA; BLEEDING; BRAIN ISCHEMIA; CANCER CONTROL; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CONSTIPATION; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DYSGEUSIA; DYSPNEA; ENDOCRINE DISEASE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; HYPOXIA; INTESTINE ISCHEMIA; KIDNEY DISEASE; LEUKOPENIA; LIMB WEAKNESS; LIVER DYSFUNCTION; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PANCREAS DISEASE; PANCREATITIS; PARESTHESIA; PROTEINURIA; QT PROLONGATION; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SIDE EFFECT; SKIN DISEASE; SLURRED SPEECH; SOLID TUMOR; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREMOR; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VISUAL DISORDER; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77957726685     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976; 36: 2807-12.
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986; 46: 467-73.
3. Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 9: 653-60.
4. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84.
5. Moeller BJ, Cao Y, Vujaskovic Z, et al. The relationship between hypoxia and angiogenesis. Sem Radiat Oncol 2004; 14: 215-21.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Revs Cancer 2003; 3: 401-10.
8. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11: 416-20.
9. Horsman MR, Siemann DW. Pathophysiological effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520-39.
10. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Revs Cancer 2002; 2: 727-39.
11. Boehm S, Rothermundt C, Hess D, et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini review. Gerontology 2010; 56: 303-9.
12. Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 2000; 57: 5-12.
13. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9. (Pubitemid 36583102)
14. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27.
15. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Revs Cancer 2005; 5: 423-35.
16. Patterson DM, Rustin GJS. Vascular damaging agents. Clin Oncol 2007; 19: 443-56.
17. Horsman MR, Murata R, Breidahl T, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Advances Exper Med Biol 2000; 476: 311-23.
18. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Revs Clin Oncol 2009; 6: 395-404.
19. Hall K, Ran S. Regulation of tumor angiogenesis by the local environment. Frontiers in Bioscience 2010; 15: 195-212.
20. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Mets Rev 2006; 25: 315-22. (Pubitemid 44922352)
21. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-31.
22. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: a review. Cancer Res 1989; 49: 6449-65. (Pubitemid 20008770)
23. Eriksen JG, Horsman MR. Tumour hypoxia - a characteristic feature with a complex molecular background. Radiother Oncol 2006; 81: 119-21.
24. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-7. (Pubitemid 44454154)
25. Ahn G-O, Brown JM. Matrix-metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008; 13: 193-205.
26. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
27. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-63. (Pubitemid 40017699)
28. Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009; 9: 999-1007.
29. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27: 4865-73.
30. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004; 13: 1171-82.
31. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
32. Horsman MR, Schmidt AB, Nielsen T, et al. Physiological changes induced by combretastatin and their significance for the therapeutic application. Mol Cancer Ther 2007; 6: 3435S.
33. Ke Q, Bodyak N, Rigor DL, et al. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vasc Pharmacol 2009; 51: 337-43.
34. Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Invest Drugs 2009; 18: 1541-8.
35. Head M, Jameson MB. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Invest Drugs 2009; 19: 295-304.
36. Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. The Oncologist 2009; 14: 612-20.
37. LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008; 26: 159-67.
38. Traynor AM, Gordon MS, Alberti D, et al. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs 2009; 28: 509-15.
39. Murata M, Siemann DW, Overgaard J, et al. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4- acetic acid. Radiat Res 2001; 156: 503-9. (Pubitemid 33027519)
40. Horsman MR, Murata M. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1518-23.